Rosiglitazone hydrochloride

SKU: orb1300588

Description

Rosiglitazone hydrochloride is a PPARγ agonist that enhances insulin sensitivity, primarily used in diabetes research. It is widely applied in both in vitro receptor binding assays and in vivo models of insulin resistance and glucose metabolism studies.

Research Area

Cell Biology, Metabolism Research, Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 302543-62-0
• MW: 393.89
• Purity: 99.79%
• Formula: C₁₈H₁₉N₃O₃S·HCl
• SMILES: Cl.CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1
• Target: TRP/TRPV Channel,Ferroptosis,Apoptosis,PPAR,Autophagy
• Solubility: H2O:< 1 mg/mL (insoluble or slightly soluble);DMSO:250 mg/mL (634.69 mM);Ethanol:73 mg/mL (185.33 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:10 mg/mL (25.39 mM)

Bioactivity

• Target IC50:
  PPARγ:40 nM (Kd)|PPARγ1:30 nM (EC50)|PPARγ2:100 nM (EC50)
• In Vitro:
  Bafetinib blocks WT Bcr-Abl autophosphorylation and its downstream kinase activity with IC50 of 11 nM and 22 nM in K562 and 293T cells, respectively. Bafetinib suppresses the growth of the Bcr-Abl-positive cell lines including K562, KU812, and BaF3/wt cells potently without effects on the proliferation of the Bcr-Abl-negative U937 cell line. Moreover, Bafetinib exhibits a dose-dependent antiproliferative effect against Bcr-Abl point mutant cell lines, such as BaF3/E255K cells. In Bcr-Abl+ leukemia cell lines, Bafetinib induces both caspase-mediated and caspase-independent cell death by blocking the phosphorylation of Bcr-Abl.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

carcinoma, cancer, bladder, Autophagy, antihyperglycemic, Apoptosis, diabetes, diabetic, BRL 49653, BRL49653, BRL-49653, BRL-49653 HCl, Inhibitor, inhibit, neuroprotection, ovarian cancer, hepatocellular, HCC, mellitus, Ferroptosis, senescence, Peroxisome proliferator-activated receptors, PPAR, PPARγ, TRPV Channel, TRPChannel, TRPVChannel, TRP Channel, Transient receptor potential channels, Rosiglitazone, Rosiglitazone HCl, Rosiglitazone hydrochloride, Rosiglitazone Hydrochloride, smoke

Compound Identifiers

PubChem CID

9865387